Entasis Therapeutics (NASDAQ:ETTX) announced its earnings results on Monday. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.44), Fidelity Earnings reports.

ETTX opened at $7.25 on Thursday. The business has a 50-day moving average price of $6.46. Entasis Therapeutics has a 12-month low of $3.97 and a 12-month high of $13.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.79 and a quick ratio of 8.79. The stock has a market cap of $91.92 million and a PE ratio of -0.59.

A number of equities analysts have weighed in on the company. ValuEngine upgraded Entasis Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Zacks Investment Research lowered Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $16.50.

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Further Reading: Outstanding Shares

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.